-

09:50:59 AM

QNRX Stock News

QNRX - Quoin Pharmaceuticals Ltd

05/24/23 8:15 AM

Nasdaq : QNRX

clinical triallow float

Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announces that its open label study evaluating QRX003 as a treatment for Netherton Syndrome

RHEA-AI

neutral

05/08/23 5:00 PM

Nasdaq : QNRX

earningslow float

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

First patient dosed in Quoin’s single arm, open label clinical trial in Netherton Syndrome patients currently receiving off-label systemic therapy Recruitment and dosing continue in Quoin’s ongoing double blinded, placebo-controlled study of QRX003 for Netherton Syndrome Following successful public

RHEA-AI

neutral

05/02/23 8:30 AM

Nasdaq : QNRX

earningslow float

Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company intends to release its first quarter 2023 financial results

RHEA-AI

neutral

03/21/23 8:30 AM

Nasdaq : QNRX

clinical triallow float

Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces the dosing of the first patient in its open label clinical trial in

RHEA-AI

neutral

03/08/23 5:08 PM

Nasdaq : QNRX

earningslow float

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Quoin announced dosing of first patient in double blinded clinical study to evaluate QRX003 for Netherton Syndrome Quoin announced initiation of a second clinical trial to evaluate QRX003 in Netherton Syndrome patients currently receiving off-label systemic therapy Continued advancement of pipeline

RHEA-AI

positive

03/02/23 4:05 PM

Nasdaq : QNRX

low float

Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company intends to release its 2022 fourth quarter and year-end

RHEA-AI

neutral

02/22/23 8:39 AM

Nasdaq : QNRX

offeringlow float

Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering of

RHEA-AI

neutral

12/13/22 8:30 AM

Nasdaq : QNRX

clinical triallow float

Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a

RHEA-AI

neutral

11/10/22 8:30 AM

Nasdaq : QNRX

earningslow float

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial Results

Company completed a public offering for aggregate gross proceeds of $16.8 million Majority of clinical sites now open in clinical study to evaluate QRX003 for Netherton Syndrome Quoin announced plans to initiate second clinical trial to evaluate QRX003 in Netherton Syndrome patients currently

RHEA-AI

very positive

11/03/22 7:00 AM

Nasdaq : QNRX

low float

Quoin Pharmaceuticals Announces Updated Timing of Third Quarter 2022 Corporate Update Conference Call to be held on Thursday November 10th

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today updated

RHEA-AI

neutral